Oral bisphosphonate use and lung cancer incidence among postmenopausal women

Meng Hua Tao, S. Chen, J. L. Freudenheim, J. A. Cauley, Karen Johnson, X. Mai, G. E. Sarto, H. Wakelee, P. Boffetta, J. Wactawski-Wende

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Bisphosphonates are common medications for the treatment of osteoporosis in older populations. Several studies, including the Women's Health Initiative (WHI), have found inverse associations of bisphosphonate use with risk of breast and endometrial cancer, but little is known about its association with other common malignancies. The objective of this study was to evaluate the association of bisphosphonate use on the incidence of lung cancer in the WHI. Patients and methods: The association between oral bisphosphonate use and lung cancer risk was examined in 151 432 postmenopausal women enrolled into the WHI in 1993-1998. At baseline and during follow-up, participants completed an inventory of regularly used medications including bisphosphonates. Results: After a mean follow-up of 13.3 years, 2511 women were diagnosed with incident lung cancer. There was no evidence of a difference in lung cancer incidence between oral bisphosphonate users and never users (adjusted hazard ratio=0.91; 95% confidence intervals, 0.80-1.04; P=0.16). However, an inverse association was observed among those who were never smokers (hazard ratio=0.57, 95% confidence interval, 0.39-0.84; P < 0.01). Conclusion: In this large prospective cohort of postmenopausal women, oral bisphosphonate use was associated with significantly lower lung cancer risk among never smokers, suggesting bisphosphonates may have a protective effect against lung cancer. Additional studies are needed to confirm our findings.

Original languageEnglish (US)
Pages (from-to)1476-1485
Number of pages10
JournalAnnals of Oncology
Volume29
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Diphosphonates
Lung Neoplasms
Incidence
Women's Health
Confidence Intervals
Endometrial Neoplasms
Osteoporosis
Breast Neoplasms
Equipment and Supplies
Population

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Tao, M. H., Chen, S., Freudenheim, J. L., Cauley, J. A., Johnson, K., Mai, X., ... Wactawski-Wende, J. (2018). Oral bisphosphonate use and lung cancer incidence among postmenopausal women. Annals of Oncology, 29(6), 1476-1485. https://doi.org/10.1093/annonc/mdy097

Oral bisphosphonate use and lung cancer incidence among postmenopausal women. / Tao, Meng Hua; Chen, S.; Freudenheim, J. L.; Cauley, J. A.; Johnson, Karen; Mai, X.; Sarto, G. E.; Wakelee, H.; Boffetta, P.; Wactawski-Wende, J.

In: Annals of Oncology, Vol. 29, No. 6, 01.06.2018, p. 1476-1485.

Research output: Contribution to journalArticle

Tao, MH, Chen, S, Freudenheim, JL, Cauley, JA, Johnson, K, Mai, X, Sarto, GE, Wakelee, H, Boffetta, P & Wactawski-Wende, J 2018, 'Oral bisphosphonate use and lung cancer incidence among postmenopausal women', Annals of Oncology, vol. 29, no. 6, pp. 1476-1485. https://doi.org/10.1093/annonc/mdy097
Tao, Meng Hua ; Chen, S. ; Freudenheim, J. L. ; Cauley, J. A. ; Johnson, Karen ; Mai, X. ; Sarto, G. E. ; Wakelee, H. ; Boffetta, P. ; Wactawski-Wende, J. / Oral bisphosphonate use and lung cancer incidence among postmenopausal women. In: Annals of Oncology. 2018 ; Vol. 29, No. 6. pp. 1476-1485.
@article{bbe66e878a1d4e1592d470c6f6604436,
title = "Oral bisphosphonate use and lung cancer incidence among postmenopausal women",
abstract = "Background: Bisphosphonates are common medications for the treatment of osteoporosis in older populations. Several studies, including the Women's Health Initiative (WHI), have found inverse associations of bisphosphonate use with risk of breast and endometrial cancer, but little is known about its association with other common malignancies. The objective of this study was to evaluate the association of bisphosphonate use on the incidence of lung cancer in the WHI. Patients and methods: The association between oral bisphosphonate use and lung cancer risk was examined in 151 432 postmenopausal women enrolled into the WHI in 1993-1998. At baseline and during follow-up, participants completed an inventory of regularly used medications including bisphosphonates. Results: After a mean follow-up of 13.3 years, 2511 women were diagnosed with incident lung cancer. There was no evidence of a difference in lung cancer incidence between oral bisphosphonate users and never users (adjusted hazard ratio=0.91; 95{\%} confidence intervals, 0.80-1.04; P=0.16). However, an inverse association was observed among those who were never smokers (hazard ratio=0.57, 95{\%} confidence interval, 0.39-0.84; P < 0.01). Conclusion: In this large prospective cohort of postmenopausal women, oral bisphosphonate use was associated with significantly lower lung cancer risk among never smokers, suggesting bisphosphonates may have a protective effect against lung cancer. Additional studies are needed to confirm our findings.",
author = "Tao, {Meng Hua} and S. Chen and Freudenheim, {J. L.} and Cauley, {J. A.} and Karen Johnson and X. Mai and Sarto, {G. E.} and H. Wakelee and P. Boffetta and J. Wactawski-Wende",
year = "2018",
month = "6",
day = "1",
doi = "10.1093/annonc/mdy097",
language = "English (US)",
volume = "29",
pages = "1476--1485",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Oral bisphosphonate use and lung cancer incidence among postmenopausal women

AU - Tao, Meng Hua

AU - Chen, S.

AU - Freudenheim, J. L.

AU - Cauley, J. A.

AU - Johnson, Karen

AU - Mai, X.

AU - Sarto, G. E.

AU - Wakelee, H.

AU - Boffetta, P.

AU - Wactawski-Wende, J.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: Bisphosphonates are common medications for the treatment of osteoporosis in older populations. Several studies, including the Women's Health Initiative (WHI), have found inverse associations of bisphosphonate use with risk of breast and endometrial cancer, but little is known about its association with other common malignancies. The objective of this study was to evaluate the association of bisphosphonate use on the incidence of lung cancer in the WHI. Patients and methods: The association between oral bisphosphonate use and lung cancer risk was examined in 151 432 postmenopausal women enrolled into the WHI in 1993-1998. At baseline and during follow-up, participants completed an inventory of regularly used medications including bisphosphonates. Results: After a mean follow-up of 13.3 years, 2511 women were diagnosed with incident lung cancer. There was no evidence of a difference in lung cancer incidence between oral bisphosphonate users and never users (adjusted hazard ratio=0.91; 95% confidence intervals, 0.80-1.04; P=0.16). However, an inverse association was observed among those who were never smokers (hazard ratio=0.57, 95% confidence interval, 0.39-0.84; P < 0.01). Conclusion: In this large prospective cohort of postmenopausal women, oral bisphosphonate use was associated with significantly lower lung cancer risk among never smokers, suggesting bisphosphonates may have a protective effect against lung cancer. Additional studies are needed to confirm our findings.

AB - Background: Bisphosphonates are common medications for the treatment of osteoporosis in older populations. Several studies, including the Women's Health Initiative (WHI), have found inverse associations of bisphosphonate use with risk of breast and endometrial cancer, but little is known about its association with other common malignancies. The objective of this study was to evaluate the association of bisphosphonate use on the incidence of lung cancer in the WHI. Patients and methods: The association between oral bisphosphonate use and lung cancer risk was examined in 151 432 postmenopausal women enrolled into the WHI in 1993-1998. At baseline and during follow-up, participants completed an inventory of regularly used medications including bisphosphonates. Results: After a mean follow-up of 13.3 years, 2511 women were diagnosed with incident lung cancer. There was no evidence of a difference in lung cancer incidence between oral bisphosphonate users and never users (adjusted hazard ratio=0.91; 95% confidence intervals, 0.80-1.04; P=0.16). However, an inverse association was observed among those who were never smokers (hazard ratio=0.57, 95% confidence interval, 0.39-0.84; P < 0.01). Conclusion: In this large prospective cohort of postmenopausal women, oral bisphosphonate use was associated with significantly lower lung cancer risk among never smokers, suggesting bisphosphonates may have a protective effect against lung cancer. Additional studies are needed to confirm our findings.

UR - http://www.scopus.com/inward/record.url?scp=85050790301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050790301&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy097

DO - 10.1093/annonc/mdy097

M3 - Article

VL - 29

SP - 1476

EP - 1485

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -